Skip to main content
ORTINGLOBE · Health Care · 2026-08-21

Ortin Global Ltd

Stage 3 · wk 1In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹15.9
-0.38% today
₹13 Cr · Micro cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Visit company website →
vs 52W High
-20.2%
₹11.2 lo₹19.9 hi
20.2% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 1
1w13w26w
Week 1 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
7.0%
200 DMA: ₹14.8 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.18x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
MA20 gently rising · +0.8% vs MA50 -1.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2024-08-26 → 2026-08-21
S? 42w
S1 13w
S2 22w
S2 9w
2024-08-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S4 1w → S1 13w → S2 2w → S3 1w → S4 7w → S2 22w → S3 4w → S2 9w → S3 1w current
Total tracked: 103 weeks across 10 stage runs.
1M
+6.6%
3M
+3.7%
6M
-3.1%
YTD
+13.7%
1Y
+6.3%
Scan Membership
Breakout Watch
Latest: 2026-06-12
3 appearances in last 60 days. First seen: 2025-09-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S3
Wk 1 · Vol x
2026-08-20S3
Wk 1 · Vol x
2026-08-19S3
Wk 1 · Vol x
2026-08-18S3
Wk 1 · Vol x
2026-08-17S32→3
Wk 1 · Vol x
2026-08-14S2
Wk 9 · Vol x
2026-08-13S2
Wk 9 · Vol x
2026-08-12S2
Wk 9 · Vol x
2026-08-11S2
Wk 9 · Vol x
2026-08-10S2
Wk 9 · Vol x
2026-08-07S2
Wk 8 · Vol x
2026-08-06S2
Wk 8 · Vol x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹16
200 DMA
₹14.8
52W High
₹19.9
52W Low
₹11.2
5D Low
₹15.5
Resistance levels (recent highs)
20d High
₹16
60d High
₹19.9
120d High
₹19.9
250d High
₹19.9
Next resistance
+0.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.